HCPCS code J3465 – Injection, voriconazole

What is HCPCS Code J3465?

HCPCS Code J3465 is the code for injection, voriconazole, 10 mg, billed as one unit for every 10 mg administered. It pays for the drug alone, not the infusion. Medicare Part B reimburses it at the average sales price (ASP) plus 6% in the physician office.

Voriconazole is a triazole antifungal approved by the FDA for serious invasive fungal infections. Pfizer markets the intravenous form as Vfend IV. J3465 sits in the J-series of HCPCS Level II, the CMS code set for drugs given other than orally.

The code was added to the HCPCS file on January 1, 2004, and its most recent action took effect on January 1, 2019. It remains valid and billable for fiscal year 2026. Any claim for IV voriconazole in an outpatient or office setting uses J3465, not the unclassified drug code J3490.

Key takeaways

HCPCS Code J3465 covers injection, voriconazole, 10 mg, billed as one unit for every 10 mg administered.

Medicare Part B pays J3465 at ASP plus 6% in the physician office, priced from the quarterly CMS ASP Drug Pricing File.

Every claim carries the 11-digit NDC of the product given, reported after the N4 qualifier on an 837P.

JW reports discarded drug, and JZ attests zero waste on single-dose vial claims from July 1, 2023 onward.

Pabau’s claims management tools capture the administration detail at the chair, so the drug line submits with its supporting fields.

Voriconazole’s FDA-approved indications include invasive aspergillosis, candidemia in non-neutropenic patients, disseminated Candida infections, esophageal candidiasis, and certain rare mold infections (Scedosporium and Fusarium species). Only claims supported by a covered diagnosis will pass medical necessity review. Billing J3465 against an unsupported ICD-10 code is a leading cause of denials for this drug.

J3465 fee schedule and Medicare reimbursement

Medicare Part B pays for HCPCS Code J3465 under the average sales price (ASP) methodology. CMS updates ASP rates quarterly, so the figures below are benchmarks only. Pull the current quarter’s ASP Drug Pricing File before you submit. Billing against a stale rate leaves the practice absorbing the difference on every vial.

Confirm the current payment amount in the quarterly CMS ASP Drug Pricing File, which sets the Part B payment limits for J-codes. The Physician Fee Schedule does not price J3465, so the MPFS lookup tool will not answer this question. The 6% add-on applies to the drug cost, and the infusion is paid separately under CPT codes 96365 to 96368.

Commercial payer rates vary significantly. Some payers reimburse at ASP + a higher or lower percentage; others use wholesale acquisition cost (WAC)-based pricing. Always verify contracted rates with each commercial payer before billing. Buy-and-bill practices should model their acquisition cost against expected reimbursement to confirm margin viability on a payer-by-payer basis.

Billing guidelines for HCPCS Code J3465

Voriconazole is typically dosed in milligrams per kilogram of body weight. That means the units billed on the claim will differ from patient to patient. Getting the quantity right is where many practices make costly errors. A standard adult loading dose of 400 mg, for example, requires billing 40 units of J3465 (40 units x 10 mg each = 400 mg).

A clean J3465 line turns on four fields: quantity, NDC, place of service, and the administration code. Miss one and the line is likely to deny. Integrated claims management software that enforces those fields at charge entry cuts the rework later.

Quantity reporting

Bill one unit of J3465 per 10 mg of voriconazole administered. Do not round down. If 390 mg is given, bill 39 units. Most payers expect the quantity field to reflect the exact dose administered, not a rounded or average dose. Document the administered dose clearly in the treatment note to support the units billed.

NDC number requirement

CMS requires the 11-digit National Drug Code (NDC) on every Part B drug claim. For J3465, include the NDC of the voriconazole product used. Add the unit qualifier (UN for units) and the quantity dispensed in NDC units. Failure to include the NDC is a hard-edit denial under CMS Medicare Claims Processing Manual Chapter 17. On an electronic claim (837P), report the qualifier N4 immediately followed by the 11-digit NDC number.

Place-of-service codes

Use POS 11 (physician office) for in-office administration on a CMS-1500. Hospital outpatient claims use POS 22 on the UB-04 form. The POS directly affects which fee schedule applies and how Medicare calculates reimbursement. Mismatched POS codes are a common source of incorrect payment and subsequent recoupment.

Administration codes to pair with J3465

J3465 covers the drug only, so the IV infusion is billed separately. Use CPT 96365 for the initial hour of therapeutic infusion, and CPT 96366 for each additional hour. Pair them with J3465 on the same claim date. Without an administration code, the drug line can be questioned as lacking a billable service.

Modifiers used with HCPCS Code J3465

CMS has specific modifier rules for J-series drug codes. Applying the wrong modifier (or omitting a required one) leads to denials, recoupment requests, or OIG scrutiny. The two most critical modifiers for J3465 are JW and JZ.

CMS’s JW/JZ policy requires practices to document the waste event in the medical record, including the amount wasted and the reason. Billing JW without that documentation in the chart is an audit trigger. JZ reporting opened as optional on January 1, 2023. CMS then made it mandatory on single-dose vial claims with no waste for dates of service on or after July 1, 2023. Check with your Medicare Administrative Contractor (MAC) for local policy variations.

ICD-10 diagnosis codes linked to J3465

Every J3465 claim requires a linked ICD-10-CM diagnosis code that establishes medical necessity. CMS and commercial payers review the reported diagnosis against their Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs) for antifungal agents. The table below lists the most commonly paired ICD-10 codes. Use the most specific code applicable to the patient’s confirmed diagnosis.

Always code to the highest level of specificity. Payers audit J3465 claims against published LCD criteria. If the patient’s diagnosis does not appear on the covered-diagnosis list in your MAC’s LCD for antifungal agents, document the clinical rationale thoroughly before billing. Using a more general code to avoid LCD review is a compliance risk.

Prior authorization requirements for J3465

Medicare Part B does not currently require prior authorization (PA) for HCPCS Code J3465. Most commercial and managed care payers do require PA before IV voriconazole is administered. Failing to obtain authorization when required leaves the practice holding the cost of a high-priced drug with no reimbursement path. Run the benefit check and the PA before infusion day, not on it.

• Check payer requirements before every infusion. PA requirements vary by payer, plan, and formulary tier. A patient’s employer plan may have different requirements than their commercial insurance carrier.
• Gather clinical documentation upfront. Most PA requests for IV voriconazole require diagnosis confirmation (culture or PCR results), prior treatment history, and prescribing physician attestation of medical necessity.
• Know your MAC’s LCD. Medicare Administrative Contractors may issue Local Coverage Determinations that specify clinical criteria even where PA is not required. Non-compliance with LCD criteria leads to post-payment audits.
• Submit requests with the correct code. PA requests should reference J3465 explicitly. Using J3490 (unclassified drug) on a PA request can delay approval or result in a denial when the claim is adjudicated against J3465.
• Build an appeals path before you need one. A PA denial workflow should cover the first-level appeal with added clinical documentation and, where the payer allows it, a peer-to-peer review request.

PA requirements for commercial payers are subject to change. Verify with each payer at the time of service, not at the time of authorization, since formulary tiers can change mid-year.

How to document medical necessity for voriconazole claims

A covered ICD-10 code gets the claim through the front door. Surviving a post-payment review takes the chart behind it. Recoupments on J3465 usually trace back to one of three thin spots: the evidence that confirmed the infection, the physician order, or the dose calculation.

Required clinical documentation elements

• Confirmed diagnosis with supporting evidence. For aspergillosis, include culture results, galactomannan assay, or imaging findings (CT chest halo sign). For candidemia, include blood culture with species identification. An ICD-10 code without supporting lab or imaging evidence is an audit risk.
• Prescribing physician order. A signed, dated order specifying voriconazole IV, dose (in mg/kg), frequency, and duration. Verbal orders must be authenticated promptly per facility policy.
• Weight-based dosing calculation. Because voriconazole is dosed per kilogram, document the patient’s current weight and show the dose calculation. This ties the administered dose (and thus the billed units) directly to the clinical record.
• Treatment failure documentation (if applicable). When voriconazole is used after another antifungal fails, document prior agents used, duration, and the reason for switching. Payers increasingly require this for step-therapy plans.
• Administration record. Nursing documentation of the actual dose administered, infusion start and stop time, and vial lot/NDC number. This is the source document that supports both the drug units billed on J3465 and the JW/JZ modifier decision.

Recovery Audit Contractors (RACs) target high-cost antifungals, so the documentation standard on injectables is higher than on an office visit. Templates tied to charge capture keep the administered dose and the billed units in step. Administration records also have to stay secure and retrievable inside the CMS response window when a records request lands.

Related HCPCS and CPT codes

Billers working voriconazole claims need the companion service codes, plus the rule for when J3465 is the wrong choice. Our HCPCS billing guides cover the neighboring drug codes that follow the same unit and NDC rules.

J3490 should never stand in for J3465. An unclassified code adds documentation work, since payers usually want an invoice or a letter of medical necessity with the claim. It also slows payment. Check the current HCPCS release to confirm a code is still active before you bill it.

How Pabau keeps J3465 claim detail with the patient record

In most practices the drug is recorded in one system and billed from another. A nurse notes the dose and the vial in the chart. Days later a biller retypes the units, the NDC, and the waste modifier into the claim. Every retype is a chance to drop a field the payer checks.

Pabau, practice management software for medical and aesthetic practices, keeps that detail on the patient record instead. The administered dose, the product used, and the infusion time are captured where the treatment happens, then carried into charge capture. The biller works from what the clinician documented rather than from a second transcription.

Claims management in Pabau then holds the drug line together before submission, with the unit count tied to the documented dose. Fewer J3465 lines come back for a missing NDC or an unsupported unit count. Your team spends less time reworking claims it already billed once.

Streamline your J-code billing workflows with Pabau

Pabau’s integrated claims management tools help you capture drug administration details, enforce NDC documentation, and submit cleaner J-code claims. See how it works in a live demo.

Book a demo

Conclusion

Billing voriconazole is a documentation problem more than a coding problem. The code is unambiguous, the unit is 10 mg, and CMS republishes the payment basis every quarter. What decides the outcome is whether the chart shows the dose given, the product used, and what happened to the rest of the vial.

Capture those three at the point of care and J3465 denials become rare. Leave them to be reconstructed at billing and the practice eventually eats the cost of an expensive drug. Book a demo to see how Pabau keeps drug administration detail attached to the claim that bills it.

Continue your research

Confused about when a denial is appealable? Denial management in healthcare covers the full appeals workflow for claim denials, including documentation strategies for J-code disputes.

Need a cleaner claims process? Pabau’s claims management software integrates documentation and charge capture to reduce drug billing errors from the point of administration.

Want to understand how drug claims move through the revenue cycle? Revenue cycle management explained breaks down each stage from charge capture to payment posting for specialty practices.

Frequently asked questions